CA9 and neoplasm: Since the discovery of CAIX as a hypoxictumor biomarker,18−20 numerous studies have used antibodies, small-moleculecompounds,and nanoparticles conjugated to fluorescent or radioactive elementsdesigned both for tumor imaging and cancer treatment.1−3,5,14,21−54 Several small-molecule probes have reached clinical trials.